KW-8232
- CAS No.
- 217813-15-5
- Chemical Name:
- KW-8232
- Synonyms
- KW-8232;KW8232,KW 8232;Methanone, [3-[bis(4-hydroxyphenyl)methyl]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl][4-(2-chlorophenyl)-1-piperazinyl]-, methanesulfonate (1:1)
- CBNumber:
- CB99624192
- Molecular Formula:
- Molecular Weight:
- 705.27
- MDL Number:
- MFCD34368498
- MOL File:
- 217813-15-5.mol
KW-8232 Chemical Properties,Uses,Production
Uses
KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2[1].
Biological Activity
KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2[1]. KW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE2 in mouse osteoblastic cells[1].KW-8232 possesses anti-viral activity against SARS-CoV-2 (EC50 ~1.2 μM )[2]. KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production[1].
in vivo
KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production[1].
| Animal Model: | male Sprague-Dawley rats (5-week-old)[1]. |
| Dosage: | 1, 3, 10, and 30 mg/kg. |
| Administration: | Orally once daily beginning 1 day prior to neurectomy for 28 days. |
| Result: | Decreased urinary calcium excreation in the neurectomized rats only at 30 mg/kg. |
IC 50
EP
References
[1]. Uchii M, et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. Jpn J Pharmacol. 1998 Oct;78(2):241-3. [2]. Shiwei Wang, et al. A Transferable Deep Learning Approach to Fast Screen Potent Antiviral Drugs against SARS-CoV-2. bioRxiv. 2020.
KW-8232 Preparation Products And Raw materials
Raw materials
Preparation Products
KW-8232 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Aladdin Scientific | tp@aladdinsci.com | United States | 52924 | 58 | |
| TargetMol Chemicals Inc. | +17819995354 | marketing@targetmol.com | United States | 19939 | 58 |
| Kaifeng Mingren Pharmaceutical Co.,LTD | 0371-65741762 | sales@hasunny.com | China | 2380 | 58 |
| RD International Technology Co., Limited | 18024082417 | market@ubiochem.com | China | 9835 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 26070 | 58 |
| Biosynth Biological Technology (Suzhou) Co Ltd | 51288865780 | sales@biosynth.com | China | 6051 | 58 |
